FIRMS REQUESTING PRE-SUBMISSION MEETINGS SPECIFIED IN HOUSE FDA REFORM BILL MUST PROVIDE DETAILED PROTOCOLS; CDRH PREPARING FOR IMPLEMENTATION OF LEGISLATION
This article was originally published in The Gray Sheet
Sponsors of premarket approval applications seeking a pre-submission meeting to gain feedback on clinical trial protocols must provide the agency with a detailed outline of proposed studies and background on company attendees at the meeting, according to the House Commerce Committee's Oct. 6 report on the stand-alone FDA device reform bill (HR 1710).
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.